Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma -: Results of a prospective Randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

被引：0

作者：

Hiddemann, W

Dreyling, MH

Forstpointner, R

Kneba, M

Woermann, B

Lengfelder, E

Schmits, R

Reiser, M

Metzner, B

Schmitz, N

Truemper, L

Eimermacher, H

Parwaresch, R

机构：

[1] Univ Munich, Hosp Grosshadern, Dept Internal Med 3, D-80539 Munich, Germany

[2] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[3] Hosp Braunschweig, Dept Internal Med, Braunschweig, Germany

[4] Univ Heidelberg, Hosp Mannheim, Dept Internal Med 3, D-6900 Heidelberg, Germany

[5] Univ Hosp Homburg Saar, Dept Internal Med 1, Homburg, Germany

[6] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[7] Hosp Oldenburg, Dept Internal Med 2, Oldenburg, Germany

[8] Gen Hosp St Georg, Dept Internal Med, Hamburg, Germany

[9] Univ Hosp Goettingen, Dept Internal Med, Gottingen, Germany

[10] St Marien Hosp, Dept Med, Hagen, Germany

[11] Univ Hosp Schleswig Holstein, Dept Hematopathol, Kiel, Germany

来源：

BLOOD | 2003年 / 102卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

352

引用

页码：104A / 104A

页数：1

共 50 条

[11] Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lyphoma After Initial Immuno-Chemotherapy (R-CHOP) Or Chemotherapy Alone: Analysis Of 940 Patients Treated In Prospective Randomized Trials Of The German Low Grade Lymphoma Study Group (GLSG)
Hiddemann, Wolfgang
Dreyling, Martin H.
Metzner, Bernd
Pfreundschuh, Michael
Wilhelm, Martin
Lengfelder, Eva
Hess, Georg
Hallek, Michael
Schmitz, Norbert
Pott, Christiane
Fischer, Thomas
Forstpointner, Roswitha
Hoster, Eva
Unterhalt, Michael
BLOOD, 2013, 122 (21)
[12] The addition of Rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL):: Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG).
Hiddemann, W
Unterhalt, M
Dreyling, M
Hossfeld, DK
Lengfelder, E
Metzner, B
Pfreundschuh, M
Kneba, M
Fricke, HJ
Böck, HP
Schmitz, N
Koch, P
Fuchs, R
BLOOD, 2002, 100 (11) : 92A - 92A
[13] Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)
Schmidt, Christian
Zoellner, Anna-Katharina
Jurinovic, Vindi
Soekler, Martin
Forstpointner, Roswitha
Haubner, Sascha
Buske, Christian
Viardot, Andreas
Keller, Ulrich
Pott, Christiane
Graeven, Ullrich
Marks, Reinhard
Haenel, Mathias
Liersch, Ruediger
Duerig, Jan
Hoster, Eva
Unterhalt, Michael
Hiddemann, Wolfgang
BLOOD, 2018, 132
[14] Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Hiddemann, W
Dreyling, M
Unterhalt, M
Repp, R
Hermann, S
Haenel, A
Metzner, B
Pott, C
Hartmann, F
Parwaresch, R
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 558S - 558S
[15] The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymhoma but not in mantle cell lymphoma: Results of two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG).
Hiddemann, W
Forstpointner, R
Kneba, M
Schmitz, N
Schmits, R
Metzner, B
Reiser, M
Lengfelder, E
Woermann, B
Harder, H
Hegewisch-Becker, S
Berdel, W
Hess, G
Eimermacher, H
Aldaoud, A
Planker, M
Parwaresch, R
Dreyling, M
Unterhalt, M
BLOOD, 2004, 104 (11) : 50A - 50A
[16] The addition of rituximab to frontline chop significantly improves time to treatment failure and response duration in all flipi risk groups of patients with advanced-stage follicular lymphoma: Results of a randomized trial of the german low-grade lymphoma study group
Hoster, E.
Unterhalt, M.
Buske, C.
Dreyling, M.
Hiddemann, W.
ANNALS OF ONCOLOGY, 2008, 19 : 181 - 181
[17] The addition of rituximab to a fludarabine combination (R-FCM) significantly improves remission rates and overall survival in recurrent follicular as well as mantle cell lymphoma - Followup of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Dreyling, M
Forstpointner, R
Ludwig, W
Gramatzki, M
Boeck, H
Haenel, M
Wandt, H
Parwaresch, R
Unterhalt, M
Hiddemann, W
ANNALS OF ONCOLOGY, 2005, 16 : 110 - 111
[18] Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
Lenz, G
Dreyling, M
Hoster, E
Wörmann, B
Dührsen, U
Metzner, B
Eimermacher, H
Neubauer, A
Wandt, H
Steinhauer, H
Martin, S
Heidemann, E
Aldaoud, A
Parwaresch, R
Hasford, J
Unterhalt, M
Hiddemann, W
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 1984 - 1992
[19] Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas:: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Hiddeman, W
Forstpointner, R
Dreyling, M
Gramatzki, M
Böck, HP
Haenel, M
Seymour, JF
Unterhalt, M
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 566S - 566S
[20] Rituximab maintenance after R-FCM salvage therapy in patients with follicular and mantle cell lymphomas - Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Unterhalt, M.
Forstpointner, R.
Dreyling, M.
Gramatzki, M.
Bock, H. P.
Hanel, Annette
Seymour, J.
Planker, M.
Duhrsen, U.
Wilms, K.
Clemens, M.
Ludwig, W. D.
Wandt, H.
Pasold, R.
Hiddemann, W.
ANNALS OF HEMATOLOGY, 2006, 85 : 36 - 37

← 1 2 3 4 5 →